InvestLog
ROIV Roivant Sciences Ltd. logo

ROIV Roivant Sciences Ltd.

Healthcare
$29.96-2.98%ClosedMarket Cap: $21.55B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.65

P/S

2608.88

EV/EBITDA

-15.78

DCF Value

$2.88

FCF Yield

-3.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

84.4%

Operating Margin

-15560.6%

Net Margin

-3629.2%

ROE

-6.9%

ROA

-5.2%

ROIC

-23.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 null$2.5M$303.0M$—
FY null$8.3M$-299.8M$—
Q3 null$2.0M$-265.9M$—
Q2 null$1.6M$-113.5M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$36.17

Target (Median)

$37.00

Target Range

$30.00 - $42.00

2 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-05-21
TD CowenBuy
2026-05-21
CitigroupBuy
2026-05-21
Piper SandlerOverweight
2026-04-16
HC Wainwright & Co.Buy
2026-03-04

Trading Activity

Insider Trades

View All
Venker Ericofficer: President & Immunovant CEO
SellFri May 22
Venker Ericofficer: President & Immunovant CEO
SellFri May 22
Venker Ericofficer: President & Immunovant CEO
SellFri May 22
Pulik Richardofficer: CFO
SellFri May 22
Venker Ericofficer: President & Immunovant CEO
SellWed Apr 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

GB

Exchange

—

Beta

1.14

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Peers

ASND logoASNDBBIO logoBBIOEXAS logoEXASIONS logoIONSJAZZ logoJAZZMRNA logoMRNARNA logoRNARPRX logoRPRXRVMD logoRVMDSMMT logoSMMT